Opinion|Videos|November 30, 2023
Urology Perspective on Radiation Toxicity in Prostate Cancer
Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Advertisement
Advertisement
Trending on Urology Times
1
Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD
2
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
5